Enzymotec (NASDAQ: ENZY) is one of 35 publicly-traded companies in the “Commodity Chemicals” industry, but how does it contrast to its rivals? We will compare Enzymotec to similar companies based on the strength of its profitability, risk, earnings, valuation, dividends, analyst recommendations and institutional ownership.

Institutional & Insider Ownership

27.9% of Enzymotec shares are held by institutional investors. Comparatively, 69.9% of shares of all “Commodity Chemicals” companies are held by institutional investors. 7.9% of shares of all “Commodity Chemicals” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.


This table compares Enzymotec and its rivals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Enzymotec -14.52% -3.88% -3.58%
Enzymotec Competitors -27.79% 24.43% 5.42%

Valuation and Earnings

This table compares Enzymotec and its rivals revenue, earnings per share (EPS) and valuation.

Gross Revenue EBITDA Price/Earnings Ratio
Enzymotec $47.01 million -$4.56 million -38.97
Enzymotec Competitors $4.37 billion $978.27 million 29.06

Enzymotec’s rivals have higher revenue and earnings than Enzymotec. Enzymotec is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Volatility and Risk

Enzymotec has a beta of 1.24, meaning that its share price is 24% more volatile than the S&P 500. Comparatively, Enzymotec’s rivals have a beta of 1.16, meaning that their average share price is 16% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of recent ratings and price targets for Enzymotec and its rivals, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Enzymotec 0 2 0 0 2.00
Enzymotec Competitors 188 995 1266 55 2.47

Enzymotec currently has a consensus target price of $8.00, suggesting a potential downside of 29.20%. As a group, “Commodity Chemicals” companies have a potential upside of 1.66%. Given Enzymotec’s rivals stronger consensus rating and higher possible upside, analysts clearly believe Enzymotec has less favorable growth aspects than its rivals.


Enzymotec rivals beat Enzymotec on 10 of the 12 factors compared.

Enzymotec Company Profile

Enzymotec Ltd. is a nutritional ingredients and medical foods company. The Company’s technologies, research expertise and clinical validation process enables it to develop solutions across a range of products. The Company operates in two segments: Nutrition segment and VAYA Pharma segment. Both of the Company’s segments offer a range of products that leverage its lipid-related offerings. Its product suite addresses the entire human life-cycle, from infancy to old age, and comprises ingredients in products ranging from infant formula to nutritional supplements, as well as branded medical foods, sold only under a doctor’s supervision. It markets its product portfolio to established global consumer companies and physicians and target large and growing consumer health and wellness markets. The Company’s clinically-validated products include bio-functional lipid-based compounds designed to address dietary needs, medical disorders and common diseases.

Receive News & Ratings for Enzymotec Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzymotec Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.